ICU vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ICU exhibits extreme fundamental fragility, highlighted by a Piotroski F-Score of 0/9, indicating severe financial distress across all measured health dimensions. While the company shows explosive revenue growth (526.90% YoY) and is narrowing its quarterly losses, the operating margin of -718.09% and a -295.15% ROE demonstrate a failure to translate growth into operational viability. The stock is a speculative biotech play with a massive historical price collapse (-99.8% over 5 years), currently trading as a high-risk asset despite optimistic analyst price targets.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ICU vs JNJ: Head-to-Head Comparison
This page compares SeaStar Medical Holding Corporation (ICU) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.